Paasa Logo
Taysha Gene Therapies, Inc. logo
TSHANASDAQMarket closedOpens 9:30am ET

Taysha Gene Therapies, Inc.

$4.67Last updated
-$0.12 (2.51%)Past day
Timezone

Taysha Gene Therapies, Inc. (NASDAQ: TSHA) is trading at $4.67, about ₹448 at today's USD/INR rate, as of 25 Sep 2026, 4:00 PM ET, down 2.51% today. Indian residents can buy Taysha Gene Therapies from India on Paasa under the RBI's Liberalised Remittance Scheme.

Quote

Open:$4.81
Previous close:$4.79
Volume:3.10M

Today's low

$4.67

Today's high

$4.84

52 week low

$3.06

52 week high

$7.30

TSHA opened at $4.81, closed previously at $4.79, and has traded between $3.06 and $7.30 over the past 52 weeks.

About

Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.

Country
US
CEO
Sean Nolan
Exchange listed on
NASDAQ
Industry
Biotechnology
Base currency
USD
Full Time Employees
99
Sector
Healthcare
IPO date
24/09/2020

Key statistics

Avg. volume

3.11M

Market cap

$1.49B

P/E Ratio

-11.05

Price-to-sales ratio

272.33

Enterprise value

$1.09B

Free cash flow yield

-9.08%

Debt-to-equity ratio

0.14

Return on equity

-56.19%

ROIC

-34.46%

Beta

1.17

Dividend yield

0.00%

Last dividend

$0.00

Financial overview

Revenue

$9.77M

Earnings per share

-$0.34

Free cash flow

-$93.83M

Net profit margin

-2728.04%

Gross margin

83.96%

EBITDA

-$107.79M

Revenue growth

17.28%

Similar securities

This is not an investment recommendation

How to buy Taysha Gene Therapies from India

Indian residents can buy Taysha Gene Therapies shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.

  1. Open a Paasa account

    Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.

  2. Add funds under LRS

    Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars.

  3. Search for Taysha Gene Therapies and place an order

    Find Taysha Gene Therapies by name or by its ticker, TSHA, and choose an order type. You can buy by amount or by quantity — fractional shares mean there is no minimum trade size. Taysha Gene Therapies trades 7:00 pm – 1:30 am IST; orders can only execute during that window.

  4. Track holdings and download tax reports

    Follow your Taysha Gene Therapies position in USD and INR. Taysha Gene Therapies pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.

Read the full guide: how to invest in Taysha Gene Therapies from India

Trading and taxes when buying Taysha Gene Therapies from India

Trading and limits

Trading hours
9:30 am – 4:00 pm ET
LRS limit
$250,000Per financial year, under the RBI's Liberalised Remittance Scheme.

Tax for Indian residents

TCS on remittance
20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
Capital gains in India
12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
Dividends
NoneTaysha Gene Therapies does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
US estate tax
May applyUS-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons.US estate tax calculator

Custody. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.

FAQs

Can Indian residents buy Taysha Gene Therapies stock?

Yes. Taysha Gene Therapies (TSHA) has been listed on NASDAQ since 2020, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.

How much does one Taysha Gene Therapies share cost in rupees?

One Taysha Gene Therapies share is $4.67 — about ₹448 at a USD/INR rate of 95.92 on 25 Sep 2026. Both the Taysha Gene Therapies price and the rupee rate move during the day, so the rupee cost changes with them.

What are the LRS and TCS rules for buying Taysha Gene Therapies from India?

Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.

Can I buy whole shares of Taysha Gene Therapies?

Yes. One Taysha Gene Therapies share is $4.67, and you can buy as many whole shares as you like. You can also buy by amount rather than by quantity: there is no minimum trade size, and Paasa supports fractional investing in Taysha Gene Therapies.

How are gains on Taysha Gene Therapies shares taxed in India?

The US does not levy capital gains tax on shares for Indian residents, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the USD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Taysha Gene Therapies price. Paasa issues a capital-gains statement for your return.

Does Taysha Gene Therapies pay a dividend?

No. Taysha Gene Therapies does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.

When can I trade Taysha Gene Therapies from India?

NASDAQ trades 7:00 pm – 1:30 am IST in Indian time, so the close lands after midnight. The window shifts to 8:00 pm – 2:30 am IST when the US is on standard time. Orders can only execute during that window.

Is there estate or inheritance tax on Taysha Gene Therapies shares held from India?

US-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons. It applies to your overall holdings in that jurisdiction rather than to any one position. Paasa's US estate tax calculator shows the exposure for a given portfolio value.

Do I have to declare Taysha Gene Therapies shares in my Indian tax return?

Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Taysha Gene Therapies holding, its cost and its closing value.

How do I sell Taysha Gene Therapies and bring the money back to India?

You sell during market hours (7:00 pm – 1:30 am IST) and the proceeds settle in USD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.